PointState Capital’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

PointState Capital’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-40,000	Closed	-$31.8M	–	153
2014 Q4	$31.8M	Buy	40,000 +25,000	+167%	+$13.5M	0.54%	52
2014 Q3	$5.99M	Sell	15,000 -20,000	-57%	-$5.36M	0.11%	70
2014 Q2	$9.44M	Buy	35,000 +3,680	+12%	+$790K	0.12%	80
2014 Q1	$6.82M	Buy	+31,320	New	+$8.73M	0.11%	82

Other funds holding TTPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PointState Capital's TTPH Position: Q1 2015 in Review

PointState Capital sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2015, closing a stake of 40,000 shares — an estimated $31.8M sold.

PointState Capital first reported a position in TTPH in Q1 2014 and held it in 4 quarters. The position peaked at $31.8M in Q4 2014. 130 funds tracked by Wall St. Rank hold TTPH as of Q1 2015.

PointState Capital reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
PointState Capital sold 40,000 Tetraphase Pharmaceuticals, Inc. shares in Q1 2015, an estimated $31.8M.
PointState Capital first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
PointState Capital's Tetraphase Pharmaceuticals, Inc. position peaked at $31.8M in Q4 2014.
130 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2015.

Based on PointState Capital's 13F filing for Q1 2015, filed 15 May 2015.